Key result
Aliskiren prevents hyperhomocysteinemia-induced myocardial fibrosis and diastolic dysfunction in mice.
Why the study?
Does aliskiren prevent myocardial fibrosis in preclinical models of hyperhomocysteinemia?
Does aliskiren prevent myocardial fibrosis in preclinical models of hyperhomocysteinemia?
Answers are grounded in this paper and cite their sources.
Aliskiren demonstrates direct anti-fibrotic effects on myocardial matrix turnover and improves diastolic function in preclinical models of myocardial fibrosis.
Myocardial fibrosis, a major pathophysiologic substrate of heart failure with preserved ejection fraction (HFPEF), is modulated by multiple pathways including the renin-angiotensin system. Direct renin inhibition is a promising anti-fibrotic therapy since it attenuates the pro-fibrotic effects of renin in addition to that of other effectors of the renin-angiotensin cascade. Here we show that the oral renin inhibitor aliskiren has direct effects on collagen metabolism in cardiac fibroblasts and prevented myocardial collagen deposition in a non-hypertrophic mouse model of myocardial fibrosis. Adult mice were fed hyperhomocysteinemia-inducing diet to induce myocardial fibrosis and treated concomitantly with either vehicle or aliskiren for 12 weeks. Blood pressure and plasma angiotensin II levels were normal in control and hyperhomocysteinemic mice and reduced to levels lower than observed in the control group in the groups treated with aliskiren. Homocysteine-induced myocardial matrix gene expression and fibrosis were also prevented by aliskiren. In vitro studies using adult rat cardiac fibroblasts also showed that aliskiren attenuated the pro-fibrotic pattern of matrix gene and protein expression induced by D,L, homocysteine. Both in vivo and in vitro studies demonstrated that the Akt pathway was activated by homocysteine, and that treatment with aliskiren attenuated Akt activation. In conclusion, aliskiren as mono-therapy has potent and direct effects on myocardial matrix turnover and beneficial effects on diastolic function.
No takes yet. Share an insight, caveat, or question.
Zhi et al. (2013) studied Myocardial fibrosis. Aliskiren vs. Vehicle was evaluated on Myocardial fibrosis and diastolic function (p=<0.05). Aliskiren prevented hyperhomocysteinemia-induced myocardial collagen deposition and diastolic dysfunction in mice, demonstrating direct anti-fibrotic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: